New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 10, 2012
10:35 EDTALXNAlexion says data confirm long-term safety, efficacy of chronic Soliris therapy
Alexion Pharmaceuticals announced the presentation of new data demonstrating the long-term benefits of Soliris in patients with paroxysmal nocturnal hemoglobinuria, a debilitating, ultra-rare and life-threatening blood disorder. Data including the clinical benefits of Soliris in the treatment of patients with PNH and atypical hemolytic uremic syndrome were presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta. The company said ten-year data from a large cohort of patients with PNH from the United Kingdom confirm the long-term safety and efficacy of chronic Soliris therapy and demonstrate the impact of Soliris on quality of life. The long-term safety of Soliris was also demonstrated in PNH clinical development trials in which patients were treated continuously with Soliris and followed for up to 5.5 years and other Soliris data was presented as well.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 5, 2015
16:50 EDTALXNAlexion says eculizumab trial efficacy endpoint occurred in 18.8% of patients
Subscribe for More Information
07:57 EDTALXNDeutsche sees AbbVie, BioMarin outperforming near-term
Deutsche Bank analyst Robyn Karnauskas expects shares of AbbVie (ABBV) and BioMarin (BMRN) to outperform in the near-term following recent weakness in the biotech sector. On AbbVie, Karnauskas thinks data readouts in 2015 could add $15-$25 per share over time. For BioMarin, the analyst thinks only three of the five pipeline readouts need to work in 2015. The company's takeout valuation could be up to $217 per share if data for BMN-111 for Achondroplasia, Drisapsrsen for Duchenne muscular dystrophy and BMN 270 for hemophilia are positive, Karnauskas believes. The analyst also recommends buying Celgene (CELG) and Alexion (ALXN) on any weakness for upside in the second half of 2015.
May 4, 2015
07:26 EDTALXNWorldwide Business Research to hold a conference
BioNetwork East 2015 Partnering Conference is being held in Miami on May 4-6.
April 27, 2015
08:26 EDTALXNAlexion coverage assumed with an Outperform at Oppenheimer
Subscribe for More Information
April 24, 2015
08:33 EDTALXNAlexion has reached attractive entry point, says SunTrust
Subscribe for More Information
April 23, 2015
11:23 EDTALXNAlexion weakness a buying opportunity, says Cowen
06:41 EDTALXNAlexion backs FY15 non-GAAP EPS view $5.60-$5.80, consensus $5.87
Subscribe for More Information
06:39 EDTALXNAlexion reports Q1 non-GAAP EPS $1.28, consensus $1.33
Reports Q1 revenue $600.3M, consensus $591.38M. Reports Q1 net product sales of Soliris $600.3M vs. $566.6M a year ago.
April 22, 2015
15:50 EDTALXNNotable companies reporting before tomorrow's open
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use